Poniard Pharmaceuticals Stock Net Income
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Poniard Pharmaceuticals fundamentals help investors to digest information that contributes to Poniard Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Poniard Pink Sheet. The fundamental analysis module provides a way to measure Poniard Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poniard Pharmaceuticals pink sheet.
Poniard |
Poniard Pharmaceuticals Company Net Income Analysis
Poniard Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Poniard Pharmaceuticals Net Income | (30.05 M) |
Most of Poniard Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poniard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Poniard Pharmaceuticals reported net income of (30.05 Million). This is 108.81% lower than that of the Biotechnology sector and 142.9% lower than that of the Health Care industry. The net income for all United States stocks is 105.26% higher than that of the company.
Poniard Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poniard Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Poniard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Poniard Pharmaceuticals by comparing valuation metrics of similar companies.Poniard Pharmaceuticals is currently under evaluation in net income category among its peers.
Poniard Fundamentals
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Number Of Shares Shorted | 47.72 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Net Income | (30.05 M) | ||||
| Cash And Equivalents | 1.98 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.57 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 0.76 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (24.28 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (3.79) X | ||||
| Target Price | 1.0 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 29 | ||||
| Total Asset | 11.64 M | ||||
| Retained Earnings | (438.94 M) | ||||
| Working Capital | 3.6 M | ||||
| Current Asset | 5.22 M | ||||
| Current Liabilities | 1.62 M | ||||
| Z Score | -55.1 | ||||
| Net Asset | 11.64 M |
About Poniard Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poniard Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poniard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poniard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |